Literature DB >> 32306901

Low dose combined oral contraceptives induced thrombotic anterior wall myocardial infarction: a case report.

Alaa Rahhal1, Fadi Khir2, Mohammad Adam2, Amer Aljundi3, Mohammed Khalil Mohsen4, Jassim Al-Suwaidi4.   

Abstract

BACKGROUND: Combined oral contraceptive pills are associated with an established risk for venous thrombosis; however, their risk for arterial thrombosis remains uncertain, especially with the development of low dose new generations of combined oral contraceptive. Arterial thrombosis is less likely to occur with the use of oral contraceptive pills in the absence of cardiovascular risk factors. CASE
PRESENTATION: We report a 35-year old female with no cardiovascular risk factors who presented with thrombotic anterior wall myocardial infarction 6 months after using a third generation low dose combined oral contraceptive pills (Marvelon; ethinylestradiol 30 mcg and desogestrel 150 mcg).
CONCLUSION: Third generation low dose combined oral contraceptives may lead to myocardial infarction in young women, even in the absence of other cardiovascular risk factors.

Entities:  

Keywords:  Case report; Myocardial infarction; Oral contraceptives

Year:  2020        PMID: 32306901     DOI: 10.1186/s12872-020-01462-9

Source DB:  PubMed          Journal:  BMC Cardiovasc Disord        ISSN: 1471-2261            Impact factor:   2.298


  3 in total

1.  Acute Nonatherosclerotic Coronary Thromboembolism Presenting with an Inferior STEMI in a Patient on Oral Contraception.

Authors:  Nabil Braiteh; Raheel Chaudhry; Ibraheem Rehman; Jowana Breiteh; Alon Yarkoni
Journal:  Case Rep Cardiol       Date:  2021-12-24

2.  Low-Dose Oral Contraceptives and Spontaneous Coronary Artery Dissection With Heavy Clot Burden in a Nonpregnant Woman.

Authors:  Gaspar Del Rio-Pertuz; Juthipong Benjanuwattra; Saif El Nawaa; Ankush Lahoti; Scott Shurmur
Journal:  J Investig Med High Impact Case Rep       Date:  2022 Jan-Dec

Review 3.  Premature Myocardial Infarction: A Rising Threat.

Authors:  Meral Kayikcioglu; Hasan Selçuk Ozkan; Burcu Yagmur
Journal:  Balkan Med J       Date:  2022-03-14       Impact factor: 2.021

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.